AI Product

Foundation Model Platform

Foundation Model Platform including REPRESS for microRNA binding and mRNA degradation prediction, plus complementary models for RNA processing and editing…

Intelligence Summary

Product
  • Active
  • Verified public sources
  • Developer Deep Genomics
  • Category Biotechnology
  • Status Active
  • Latest update 2015: Deep Genomics founded in Toronto by Brendan Frey per team page (CSV may list 2014).
  • Documentation Official page
  • Last reviewed Jul 2026
5 Technologies

Official product page

Target customer

Biopharmaceutical R&D teams, RNA therapeutics developers, and genomic medicine researchers designing precision therapies from sequence data.

Features & capabilities

Industries: AI in Healthcare; Biotechnology

Related reports

Related insights

Overview

Foundation Model Platform including REPRESS for microRNA binding and mRNA degradation prediction, plus complementary models for RNA processing and editing supporting therapeutic target identification and ASO, siRNA, and mRNA design.

Product and company

Foundation Model Platform is a verified product offering linked to the Brel Digital company profile for Deep Genomics.

Use cases

Foundation Model Platform including REPRESS for microRNA binding and mRNA degradation prediction, plus complementary models for RNA processing and editing supporting therapeutic target identification and ASO, siRNA, and mRNA design.

Target customer

Biopharmaceutical R&D teams, RNA therapeutics developers, and genomic medicine researchers designing precision therapies from sequence data.

Technologies

Primary technologies assigned from the linked company profile: Deep Learning, Healthcare Analytics, Large Language Models, Machine Learning, Predictive Analytics.

Sources and references

  • Official product / company source: https://www.deepgenomics.com/news/deep-genomics-expands-ai-foundation-model-platform-decoding-rna-biology/
  • Supporting source: https://www.deepgenomics.com/team

Product facts are limited to information already verified on the linked Brel company profile and its cited official URLs. No speculative capabilities are added.

Last reviewed

This product profile was last reviewed on 2026-07-14.

Correction request

If this product record is inaccurate or outdated, submit a correction through Brel Digital’s Corrections Policy.

Features and capabilities

  • Foundation Model Platform including REPRESS for microRNA binding and mRNA degradation prediction, plus complementary mode
  • REPRESS for microRNA binding
  • mRNA degradation prediction
  • plus complementary models for RNA processing
  • editing supporting therapeutic target identification
  • and mRNA design

Extracted from the linked company product description already verified on Brel. No capabilities were invented.

Sources and references

This article draws on publicly available company information, official websites, filings, interviews, announcements, and other cited sources. Information may change over time.

Enquire about this product profile

Messages are delivered to contact@breldigital.com.